Skip to main content

Table 3 Clinical score does not correlate with pathology in the early stages of disease (day 1–10).

From: Bioluminescence in vivo imaging of autoimmune encephalomyelitis predicts disease

  Bioluminescence (fold induction) Clinical score
  Brain Spinal cord Brain Spinal cord
  R P R P R P R P
Astrogliosis (GFAP) 0.704 0.015 0.713 0.010 0.120 0.298 0.233 0.501
Microgliosis (CD68) 0.886 <0.0001 0.478 0.141 0.352 0.298 0.040 0.914
T cell infiltration (CD4) 0.549 0.081 0.774 0.004 0.388 0.247 0.472 0.147
Weight loss 0.823 0.0001 0.811 0.0001 R= 0.354; P= 0.286
  1. Bioluminescence correlates with disease progression in the early stage (day 1–10), but clinical score does not. GFAP-luc mice were immunized with MOG35–55 emulsified in CFA plus pertussis toxin. Mice were evaluated for clinical signs and bioluminescence and sacrificed at day 3, 5, 7 and 10 (n = 11 mice). The same mice were part of the analysis shown in Table 1. The correlation was analyzed by Pearson correlation analysis. R: correlation coefficient.